FDA Reverses Decision About Moderna Flu Vaccine
YouTube · O7tf1-p0oHA
Quick Read
Summary
Takeaways
- ❖The FDA's initial refusal to review Moderna's mRNA flu vaccine application was highly unusual and unprecedented.
- ❖A political appointee, Vinnie Prasad, reportedly overruled senior FDA scientists in the decision to reject the application.
- ❖The FDA reversed its decision after White House intervention, agreeing to review Moderna's application with a minor modification.
- ❖The incident highlights a broader chilling effect on vaccine research and development due to regulatory uncertainty and political influence.
Insights
1FDA's Unprecedented Rejection of Moderna's mRNA Flu Vaccine Application
The FDA initially refused to even look at Moderna's application for an mRNA flu vaccine, citing insufficient data from early trials. This was highly unusual because Moderna had previously consulted with the FDA on their data package and testing plan, receiving assurances that their approach was acceptable.
Moderna had invested over a billion dollars and tested the shot on 40,000 people, following FDA's previously accepted plan. The FDA's refusal to review, rather than reject, is an extreme step typically reserved for missing application pieces or data integrity concerns.
2Political Interference by RFK Jr.'s Appointee
Reporting revealed that Vinnie Prasad, an appointee of Robert F. Kennedy Jr. in the division overseeing vaccine safety, overruled senior FDA scientists to refuse Moderna's application. Prasad insisted on an extra test that the FDA had previously deemed optional.
Reporters at Stat and the Wall Street Journal uncovered that Vinnie Prasad, Kennedy's guy, overruled senior scientists, demanding an extra test for the over 65 population that the FDA had previously said was acceptable to omit.
3FDA's Swift Reversal After White House Intervention
Following a significant outcry from the pharmaceutical industry and reported meetings involving the White House and FDA officials, the FDA reversed its decision. They agreed to review Moderna's application after all, with Moderna making a minor concession to split its approval request for different age groups.
Reporting indicated the White House met with FDA officials, who then met with Moderna, leading to the FDA agreeing to look at the application. Moderna's modification was to seek separate approval for under 65 and over 65 populations, addressing the specific data concern.
4Chilling Effect on Vaccine Research and Development
This incident is part of a broader pattern of actions, including the pulling of government support for mRNA vaccine research and scaled-back childhood vaccine recommendations, creating a 'headwind' for the vaccine industry. This regulatory chaos and political influence deter investment and innovation in critical vaccine technologies.
Kennedy pulled hundreds of billions in government support for mRNA vaccine research for future pandemics. Moderna has already pulled back on investments in other vaccine research. The CDC scaled back childhood vaccine recommendations and language on its website questions vaccine-autism links, despite scientific consensus.
Lessons
- Pharmaceutical companies should closely monitor political appointments within regulatory bodies like the FDA, as these can significantly impact approval processes and regulatory consistency.
- Investors in the biotech and pharmaceutical sectors must factor in increased regulatory risk and potential political interference when evaluating R&D investments, especially for novel technologies like mRNA.
- Advocates for public health and scientific integrity should highlight instances of political overreach in regulatory science to maintain trust and support for evidence-based decision-making.
Notable Moments
The FDA's initial refusal to even 'look at' Moderna's mRNA flu vaccine application, an action described as 'not the way these things are done' and 'basically unheard of' given prior consultations.
This set an alarming precedent for regulatory unpredictability and raised questions about the integrity of the FDA's review process, particularly concerning political influence.
The reported intervention by the White House, leading to the FDA's swift reversal on its decision to refuse Moderna's application.
This indicates that political pressure can influence regulatory outcomes, potentially undermining the independence of scientific review but also demonstrating responsiveness to industry and public outcry.
Quotes
"FDA wasn't rejecting the application, as you said, they were refusing to look at it, which is an extreme step they rarely take."
"This whole thing is just chaos. This is not how a government agency is supposed to run."
"What kind of environment are we creating, you know, for the future development of drug vaccines and other kinds of drugs?"
Q&A
Recent Questions
Related Episodes
PBS News Hour full episode, May 8, 2026
"This episode unpacks escalating US-Iran military actions in the Strait of Hormuz, a resilient yet divergent US jobs market, the ongoing political battle over congressional redistricting, and the controversial new US counterterrorism strategy."
Tom Nichols: Trump’s Speech Was Pure TRASH | Bulwark Podcast
"Tom Nichols and Tim Miller dissect Trump's 'trashy' speech, the politicization of the military, and the casual corruption eroding American institutions, contrasting it with the founding fathers' vision of patriotism."
The Jimmy Dore Live Panel Show At The Starlight Cabaret
"Jimmy Dore and his panel deliver a scathing, comedic critique of political hypocrisy, media narratives, and public figures, from congressional loyalties to COVID-19 misinformation and celebrity activism."
PBS News Hour full episode, June 16, 2026
"This episode unpacks the murky U.S.-Iran nuclear deal, the politicization of the Justice Department, rising cancer rates in Iowa, the unprecedented shutdown of powerful AI models, and a new institute reframing the enduring impact of slavery."